Clinical Study
Ipsilateral Uveitis and Optic Neuritis in Multiple Sclerosis

Eric Thouvenot,1 Frédéric Mura,2 Marie De Verdal,3 Bertrand Carlander,3 Mahmoud Charif,3 Christelle Schneider,2 Sophie Navarre,2 and William Camu3

1 Neurology Department, Hôpital Carémeau, 9 Place Robert Debré, 30029 Nimes Cedex 9, France
2 Ophthalmology Department, Hôpital Gui de Chauliac, 34295 Montpellier Cedex 5, France
3 MS Clinic, Neurology Department, Hôpital Gui de Chauliac, 34295 Montpellier Cedex 5, France

Correspondence should be addressed to Eric Thouvenot, ethouvenot@hotmail.com

Received 20 July 2012; Revised 15 October 2012; Accepted 26 October 2012

Academic Editor: Friedemann Paul

Copyright © 2012 Eric Thouvenot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Uveitis is 20 times more frequent in multiple sclerosis (MS) patients than in the general population. Methods. A retrospective study of local multiple sclerosis (n = 700) and uveitis cohorts (n = 450) described the ophthalmological and neurological characteristics of patients with multiple sclerosis and uveitis. Results. Uveitis and multiple sclerosis were associated in seven patients. The time intervals between diagnoses of MS and uveitis ranged from 6 months to 15 years. Analysis of the patients’ characteristics revealed that multiple sclerosis was associated with an older age of onset than usually expected, that is, 39 years. Uveitis was bilateral in three cases and mainly posterior (5/10). Five patients presented with acute optic neuritis (two in one eye and three in both eyes). All eyes presenting with acute optic neuritis were also affected by uveitis (P = 0.02), though not simultaneously. Conclusion. The ipsilateral association between optic neuritis and uveitis in this series of patients with multiple sclerosis may suggest a reciprocal potentiation between optic neuritis and uveitis in multiple sclerosis.

1. Introduction
Optic neuritis (ON) is the most frequent ophthalmic manifestation of multiple sclerosis (MS), occurring in ~30% of cases. In contrast, uveitis is only associated with MS in 1% of patients [1]. Similarly, uveitis is attributed to MS in 1%–3% cases of uveitis and is associated with an increased risk of severe visual disability [2, 3]. The clinical features of uveitis in MS vary considerably between reports but generally manifest as bilateral, intermediate (pars planitis) uveitis [1, 4–6]. In a series of 1855 patients with chronic anterior uveitis, MS was diagnosed in 30 patients (1.6%) [7]. Patients with MS and uveitis also present with ON more frequently than expected in MS [4, 5], but a direct pathogenic link between ON and uveitis has not yet been considered. The aim of this study was to determine the prevalence of uveitis in a cohort of patients with MS and to analyze its relationship with ON with regards to both the ophthalmological and neurological characteristics of these patients.

2. Patients and Methods
Patients from Montpellier Hospital with MS-associated uveitis were retrospectively identified through the MS clinic database in the Neurology Department (700 patients) and the uveitis database from the Ophthalmology Department (450 patients). Diagnosis of MS was assessed from clinical and MRI data according to the 2005 revised McDonald criteria for relapsing-remitting or primary progressive MS [8]. Acute uveitis was defined by the observation of acute uveitis or a report of previous acute uveitis with the presence of sequela. Uveitis was classified according to the SUN
Uveitis differential diagnosis was ruled out after comprehensive tests: that is, chest computed tomography, levels of angiotensin-converting enzyme and antinuclear antibodies, antiphospholipid antibodies, Borrelia, Rickettsia, Brucella, human immunodeficiency virus, hepatitis B and C, and toxoplasmosis and syphilis tests. ON was defined by an acute loss of visual acuity or scotoma associated with extended visual evoked potential latencies (>120 ms) and/or an MRI T2 hypersignal of the optic nerve. Bilateral ON and bilateral uveitis corresponded to acute episodes that affected both eyes simultaneously.

Patients identified with MS and uveitis were reassessed in order to confirm their characteristics regarding gender, duration and course of MS, disability caused by MS as assessed by the Expanded Disability Status Scale (EDSS) [10], onset time of uveitis and its type, course and symptoms, the presence of pars planitis or periphlebitis, and whether ON occurred in the left or right eye. Statistical analyses were performed using R software.

### 3. Results

Uveitis was identified in 5 of the 700 patients from the MS clinic (0.7%) (Table 1, patients 1–5), and MS was found in 2 patients from the uveitis database (patients 6 and 7). There were six women and one man. Patient 1 had antecedent thyroiditis, and patient 2 had recovered from hepatitis B virus. Of the seven cases, three had experienced uveitis before the onset of MS (patients 2, 4, and 7), and one patient had recurrent episodes until 3 years after the onset of MS (patient 2). There were no simultaneous manifestations of MS and uveitis. The time intervals between diagnoses ranged from 6 months to 15 years (Table 1).

Among the seven patients with MS and uveitis, one presented with primary progressive MS and six had a relapsing-remitting course (86%). In one case (Patient 1), uveitis appeared during the secondary progressive phase of MS. Mean age of onset of MS in patients with uveitis was older compared to our cohort of MS patients with no uveitis (39 years; range: 17–52 versus 31 years, resp., \( P = 0.14 \), Wilcoxon rank sum test), although this was not significant. Moreover, 4/7 patients had onset of MS when aged >45 years. EDSS scores ranged from 2 to 6 (median 4). None of the patients had a relapse of MS and uveitis at the same time. MRIs showed classical demyelinating lesions of the brain, fulfilling the Barkhof criteria for dissemination of space, for all patients. The cerebrospinal fluid disclosed oligoclonal bands in three of the four patients tested (patients 3, 5, and 6). Patients received different disease-modifying drugs, but not at the time of the study. Treatments used comprised intramuscular IFNb1a (patients 2, 5, and 6), azathioprine (patients 3, 6, 7), and methotrexate (patient 6).

Uveitis was observed in 10 eyes (bilateral in three cases) and was of various types: anterior and intermediate (pars planitis) \((n = 2)\), anterior \((n = 1)\), panuveitis \((n = 2, \) bilateral), and posterior \((n = 5)\). Disc edema and vasculitis were observed in patients 4–7, macular edema in patients 5–7 (Figure 1), and periphlebitis in only one patient (patient 5). The mean age of onset of uveitis was 40 years (range: 19–62).

One patient had antecedent acute optic neuritis before uveitis, and four patients presented with acute optic neuritis (bilateral in three cases) after uveitis. All eyes presenting with ON were also affected by uveitis \((P = 0.02, \) Fisher's test). All patients with bilateral ON also had bilateral uveitis, and those cases with unilateral ON also had uveitis in the same eye, though not at the same time.

### 4. Discussion

We have described the clinical characteristics of seven patients affected by both uveitis and MS. Uveitis was identified in 0.7% patients from the MS database, a similar proportion observed by other authors [1]. In accordance with a previous report [1], uveitis was mainly posterior (5/10 eyes) whereas MS has been generally associated with intermediate uveitis (pars planitis) [11, 12]. This overrepresentation of posterior uveitis might be caused by the retrospective inclusion of symptomatic patients, without systematic detection of MS patients with asymptomatic pars planitis, as often happens. The frequency of periphlebitis observed by Haarr in a series of 303 patients with multiple sclerosis (22%) is greater than that in our series (only one case, 14%), but we only took into account patients with MS-associated uveitis [13]. As already reported, uveitis was often bilateral [4, 5], and the mean age of uveitis onset was 40 years old [2].

Analysis of patients’ characteristics showed two interesting patterns. First, MS onset was late (39 versus 29 years for relapsing-remitting MS in the literature [14]) despite only one patient with primary progressive MS (14%). This difference was not significantly different from our MS cohort (39 versus 31 years), probably due to the small size of our group. Second, for all five patients with ON and uveitis, both inflammatory ophthalmological manifestations always occurred in the same eye. In the literature, acute ON occurs in 25% [5] to 54% [4] of MS patients with uveitis. However, to the best of our knowledge, the occurrence of ON and uveitis in the same eye has not yet been reported. Moreover, analyzing the uveitis database, we could not identify any other cases of ON-associated uveitis (i.e., without MS), suggesting a specific association between uveitis and ON in MS. This is also supported by the higher proportion of ON in patients with MS and uveitis compared to the incidence of ON in MS without uveitis. Moreover, bilateral ON was also more frequent (3/7) in our series than expected in MS without uveitis. Simultaneous bilateral optic neuritis is usually not associated with MS [15]. As bilateral ON was always associated with bilateral uveitis, we hypothesized that uveitis and ON could reciprocally potentiate each other in MS patients.

Uveitis and MS share common genetic risk factors and autoantigens [6, 12, 16]. Both diseases also involve the same type of immune response (autoactive T cells) [17]. Experimental autoimmune encephalomyelitis, using an injection of S100B (a glial cytosolic protein involved in astrocyte
Table 1: Patients’ characteristics.

| Patient | Gender | Age (years) | Age at MS onset (years) | MS course | Age at uveitis onset (years) | Uveitis evolution | Type of uveitis | Side of uveitis | Occurrence of ON | Side of ON |
|---------|--------|-------------|------------------------|-----------|-----------------------------|------------------|----------------|----------------|----------------|-----------|
| 1       | M      | 66          | 47                     | SP        | 62                          | Acute            | Anterior       | L              | yes            | L         |
| 2       | F      | 61          | 51                     | RR        | 49                          | Chronic          | Anterior and intermediate | L              | no            | —         |
| 3       | F      | 57          | 52                     | RR        | 52                          | Acute            | Anterior and intermediate | L              | yes           | L         |
| 4       | F      | 27          | 24                     | PP        | 20                          | Acute            | Posterior      | L              | no            | —         |
| 5       | F      | 22          | 17                     | RR        | 19                          | Acute            | Posterior      | B              | yes           | B         |
| 6       | F      | 54          | 49                     | RR        | 49                          | Acute            | Panuveitis     | B              | yes           | B         |
| 7       | F      | 43          | 30                     | RR        | 28                          | Acute            | Posterior      | B              | yes           | B         |
| Whole group | 1M/6F | 47          | 39                     | 5RR/2P     | 40                          | 10 U             | 8 ON            |                |                |           |

M: male; F: female; U: uveitis; ON: optic neuritis; RR: relapsing-remitting MS; P: progressive; SP: secondary-progressive MS; PP: primary progressive MS; L: left; B: bilateral.

Figure 1: Fundus photographs. Top, late-phase fluorescein angiograms from patient 6 (panuveitis, (a)) showing retinal vasculitis with cystoid macular edema (arrow) and disc leakage (arrowhead), and from patient 7 (posterior uveitis, (b)) showing retinal vasculitis with diffuse cystoid macular edema (arrow). However, because of the severity of the vitritis, the vessels are poorly visualized (a). Bottom, fluorescein angiograms from patient 5 (posterior uveitis, (c) and (d)) showing retinal occlusive vasculitis with arteriolar leakage at a late phase.

5. Conclusion

The association of MS and uveitis is well described. However, we report the first observation of a significant association of ipsilateral optic neuritis and uveitis in a series of patients with...
MS. This suggests a continuum between ophthalmologic inflammatory processes rather than an association between different autoimmune diseases. We propose that this association should be investigated in other series of patients with MS and uveitis.

Acknowledgment

The authors thank Dr. Grégoire Mercier from Montpellier University Hospital, France, for helpful advice concerning the statistical analyses.

References

[1] J. Le Scanff, P. Seve, C. Renoux, C. Broussolle, C. Confavreux, and S. Vukusic, “Uveitis associated with multiple sclerosis,” *Multiple Sclerosis*, vol. 14, no. 3, pp. 415–417, 2008.

[2] R. A. Marrie, G. Cutter, and T. Tyry, “Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis,” *Multiple Sclerosis*, vol. 17, pp. 1464–1471, 2011.

[3] J. R. Smith and J. T. Rosenbaum, “Neurological concomitants of uveitis,” *British Journal of Ophthalmology*, vol. 88, no. 12, pp. 1498–1499, 2004.

[4] M. D. Becker, A. Heiligenhaus, T. Hudde et al., “Interferon as a treatment for uveitis associated with multiple sclerosis,” *British Journal of Ophthalmology*, vol. 89, no. 10, pp. 1254–1257, 2005.

[5] S. M. Maca, M. Scharitzer, and T. Barisani-Asenbauer, “Uveitis and neurologic diseases: an often overlooked relationship,” *Wiener Klinische Wochenschrift*, vol. 118, no. 9-10, pp. 273–279, 2006.

[6] S. Schmidt, L. Wessels, A. Augustin, and T. Klockgether, “Patients with Multiple Sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation,” *Journal of the Neurological Sciences*, vol. 187, no. 1-2, pp. 49–53, 2001.

[7] A. D. Birnbaum, D. M. Little, H. H. Tessler, and D. A. Goldstein, “Etiologies of chronic anterior uveitis at a tertiary referral center over 35 years,” *Ocular Immunology and Inflammation*, vol. 19, no. 1, pp. 19–25, 2011.

[8] C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 Revisions to the ’McDonald Criteria’,” *Annals of Neurology*, vol. 58, no. 6, pp. 840–846, 2005.

[9] D. A. Jabs, “Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop,” *American Journal of Ophthalmology*, vol. 140, no. 3, pp. 509–516, 2005.

[10] J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” *Neurology*, vol. 33, no. 11, pp. 1444–1452, 1983.

[11] M. J. Donaldson, J. S. Pulido, D. C. Herman, N. Diehl, and D. Hodge, “Pars planitis: a 20-year study of incidence, clinical features, and outcomes,” *American Journal of Ophthalmology*, vol. 144, no. 6, pp. 812–817, 2007.

[12] S. C. Raja, D. A. Jabs, J. P. Dunn et al., “Pars planitis: clinical features and class II HLA associations,” *Ophthalmology*, vol. 106, no. 3, pp. 594–599, 1999.

[13] M. Haarr, “Changes of the retinal veins in multiple sclerosis,” *Acta Neurologica Scandinavica*, vol. 40, supplement 10, pp. 17–20, 1964.

[14] C. Confavreux and S. Vukusic, “Natural history of multiple sclerosis: a unifying concept,” *Brain*, vol. 129, no. 3, pp. 606–616, 2006.

[15] P. J. Parkin, R. Hierons, and W. I. McDonald, “Bilateral optic neuritis. A long-term follow-up,” *Brain*, vol. 107, part 3, pp. 951–964, 1984.

[16] W. M. Tang, J. S. Pulido, D. D. Eckels, D. P. Han, W. F. Mieler, and K. Pierce, “The association of HLA-DR15 and intermediate uveitis,” *American Journal of Ophthalmology*, vol. 123, no. 1, pp. 70–75, 1997.

[17] S. Schmidt, C. Linington, F. Zipp et al., “Multiple sclerosis: comparison of the human T-cell response to S100β and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis,” *Brain*, vol. 120, 8, pp. 1437–1445, 1997.

[18] G. Sorci, R. Bianchi, F. Riuzzi et al., “S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond,” *Cardiovascular Psychiatry and Neurology*, vol. 2010, Article ID 65648, 13 pages, 2010.

[19] G. Adamus, D. Amundson, M. Vainiene et al., “Myelin basic protein specific T-helper cells induce experimental anterior uveitis,” *Journal of Neuroscience Research*, vol. 44, pp. 513–518, 1996.